Question 2: Which infants with congenital cytomegalovirus infection benefit from antiviral therapy?

Archives of Disease in Childhood

Volumn 99, Issue 6, 2014, Pages 597-601

  Gwee, Amanda ^a,b   Curtis, Nigel ^a,b,c   Garland, Suzanne M ^a,b,c,d   Connell, Tom G ^a,b,c   Daley, Andrew J ^a,c,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; FOSCARNET; GANCICLOVIR;

ANTIVIRAL THERAPY; BILATERAL HEARING LOSS; CONGENITAL CYTOMEGALOVIRUS INFECTION; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; HEARING IMPAIRMENT; HEARING TEST; HUMAN; NERVE CELL DIFFERENTIATION; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROCONVERSION; CENTRAL NERVOUS SYSTEM DISEASE; CHORIORETINITIS; DRUG EFFECT; DRUG SAFETY; FOLLOW UP; INFANT; LIVER FUNCTION TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; CASE REPORT; EMBASE; HEPATOSPLENOMEGALY; MEDLINE; MICROCEPHALY; NEWBORN; PETECHIA;

INFECTIOUS DISEASES; PAEDIATRIC PRACTICE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; TREATMENT OUTCOME;

EID: 84901196383     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306082     Document Type: Note

References (12)

1. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17:355-63.
2. Foulon I, Naessens A, Foulon W, et al. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr 2008;153:84-8.
3. Oliver SE, Cloud GA, Sanchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009;46(Suppl 4):S22-6.
4. Royackers L, Christian D, Frans D, et al. Hearing status in children with congenital cytomegalovirus: up-to-6-years audiological follow-up. Int J Pediatr Otorhinolaryngol 2011;75:376-82.
5. Kimberlin DW, Lin C-Y, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25.
6. del Rosal T, Baquero-Artigao F, Blazquez D, et al. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period. J Clin Virol 2012;55:72-4.
7. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175:1080-6.
8. Lackner A, Acham A, Alborno T, et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. J Laryngol Otol 2009;123:391-6.
9. Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009;28:1465-70.
10. Kimberlin DW, Jester P, Sanchez PJ, et al. Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: results of a Phase III, randomized, double-blind, placebo-controlled, multinational study. ID week 2013. https://idsa.confex.com/idsa/2013/webprogram/Paper43178. html (accessed 26 Nov 2013).
11. Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr 1994;124:318-22.
12. Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010;169:1061-7.